Clinomics Europe is a Budapest-based company, established in June 2021 as the first EU subsidiary of Clinomics Inc, Korea. As the world faces the challenges of the pandemic, the healthcare sector has become crucial, and Clinomics Europe aims to make a difference. We are a rapidly growing medical biotech company devoted to developing innovative precision diagnostic devices and methods to help patients.

Our core technology utilizes genetic analysis of circulating tumor cells for early-stage cancer diagnosis, allowing us to extend the lives of cancer patients. Our unique liquid biopsy method confirms the presence of cancer by separating and identifying cancer cells in the blood. We also employ Next-Generation Sequencing (NGS) to gather vital genetic information for disease diagnosis.

By combining liquid biopsy, bioinformatics, and NGS-based cancer panels, we provide precise medical treatment to improve the quality of life for cancer patients, taking personalized medicine to new heights. In addition to our molecular cancer diagnosis and genomics research, we offer COVID-19 specific products such as high-quality qPCR testing kits and the user-friendly 1drop test device. We are committed to innovation in molecular diagnostics, constantly researching and developing cutting-edge methods using technologies like liquid biopsy and next-generation sequencing.

Our Diagnostic Services are personalized and sophisticated, keeping pace with advancements in medicine and technology. With international expansion and representation, including subsidiaries in the UK and the USA, we are dedicated to building a global business network and providing exceptional support to partners and customers. Clinomics Europe is proud of its rich Company History, starting from its establishment in 2011, with significant milestones along the way, such as certification, permits, and agreements.

We invite you to explore our website and learn more about our Products and Services, including R&D services and diagnostics, NuriBio, Generi Biotech, Altona Diagnostics, and the CD-PRIME™ system. To stay updated with the latest news and connect with us, please visit our website or get in touch using the provided contact information